Semler Scientific, Inc. USDC – Northern District of California september 4, 2025 CLASS PERIOD: march 10, 2021 – april 15, 2025LEAD PLAINTIFF DEADLINE: OCTOBER 28, 2025 Please complete the form below to contact Kaplan Fox regarding the Semler Scientific Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox Alerts Investors of Semler Scientific, Inc. (SMLR) to a Securities Class Action Deadline on October 28, 2025 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. (“Semler” or the “Company”) (NASDAQ: SMLR) on behalf of investors that purchased or otherwise acquired Semler securities between March 10, 2021 and April 15, 2025 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you purchased Semler securities during the Class Period and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 28, 2025 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. On February 28, 2025, after markets closed, the Company filed with the U.S. Securities and Exchange Commission (“SEC”) its annual report on Form 10-K for the year ended December 31, 2024 disclosing that “[i]n July 2017, the Company received an initial civil investigative demand (“CID”) from the U.S. Department of Justice (“DOJ”) pursuant to the federal False Claims Act investigating whether the Company and others may have violated the False Claims Act by marketing tests on devices that use photoplethysmography technology as reimbursable by Medicare in alleged contravention of applicable laws and regulations.” The Company also disclosed “subsequent CIDs received in February 2019, December 2021, April 2022 and April 2023 addressed to the Company or individual current or former employees related to the same investigation.” Following this news, the price of Semler’s shares fell $4.03 per share, over 9%, to close at $38.89 per share on March 3, 2025. Then, on April 15, 2025, after market closed, the Company announced it had reached an agreement with the DOJ “in principle on payment of $29.75 million to settle all claims (which amount excludes any potential relator counsel fees that may also be payable).” Following this news, the price of Semler’s shares fell $3.40 per share, nearly 10%, to close at $31.00 per share on April 16, 2025. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose (i) Semler Scientific did not disclose a material investigation by the DOJ into violations of the False Claims Act, while discussing possible violations of the False Claims Act (and aggressive DOJ enforcement thereof) in hypothetical terms; and (ii) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT:Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Dow, Inc. See the Case Semler Scientific, Inc. See the Case LifeMD, Inc. See the Case C3.ai, Inc. See the Case Snap, Inc. See the Case KinderCare Learning Companies, Inc. See the Case SelectQuote, Inc. See the Case Unicycive Therapeutics, Inc. See the Case Fiserv, Inc. See the Case Simulations Plus, Inc. See the Case Inspire Medical Systems, Inc. See the Case Western Asset Management See the Case
